BMSN/Regen Synopsis
BMSN currently has an outstanding share float of approximately 2.95 Billion. The market determines "fair market value" which is what a buyer will buy for and what a seller will sell for based on other factors such as company valuation, supply and demand.
Currently the Regen outstanding shares, or O/S is 51.5 Million. 1.5 Million were dispensed in private sales or distributions in consideration of a certain monetary or future monetary value.
BMSN will retain 30 Million preferred shares in which they will retain the title of majority stock holder. Those 30 million not only carry more weight in regards to voting rights, but are not common and therefore not tradeable.
Therefore, when Regen is issued a ticker from FINRA, the tradeable share float will only be 20 million shares. 51.5 - 1.5 - 30 = 20 Million.
Here is the kicker, since BMSN will retain 58% of the shares outstanding (30 Million), they will be considered a corporate asset and increase BMSN's share price all by itself.
Since BMSN is a venture capital holding company that owns Regen, the real value will be placed on Regen which is actually producing products, or at least in the testing phase to produce them.
So considering that 4 instances of private sales of 100K shares considering $100K puts Regen private share price at $1 per share. Private shares are usually given at a much lower price than public shares. For instance, most biotech IPOs have opened this year at $5-$15 per share.
Another kicker, since BMSN is the primary shareholder, for each $1 that Regen share price is it equates to $.01 for BMSN share price at the current O/S for BMSN, i.e $30 Million / 3 Billion = .01 of real company value. Meaning, if Regen opens at $1 when the public trading starts, BMSN will automatically be worth $.01, however, it doesn't mean it will trade at that price automatically.
In regards to the FDA (and this is where the real value comes in)Regen is currently awaiting FDA approval to begin human trials on Hemaxellerate to treat aplastic anemia. Since HemaXellerate will treat a rare condition, it is also eligible for orphan drug status. This will give Regen exclusive rights to the treatment for 7 years, and it is considered to be worth 100's of millions if not a billion dollars if successful.
Now, the mother of all kickers, Regen is also developing a treatment called dCellVax which is designed as a gene silencing treatment for breast cancer. Yes, I said cancer. It would be utilized as an alternative to chemotherapy and conventional cancer treatments without the side affects of nausea, weakness, and losing all of your hair.
Now, I don't know about anyone else, but a proven dCellVax treatment alone is worth billions. A treatment that fights cancer without the typical side affects will, in my opinion, make this company a legend.
I'm sure most of you have not fully grasped what kind of company that you are invested in, but I hope you see it now. If all goes as planned, spread the word. For BMSN/Regen will be the best investment any of us have ever made.
Good luck to you all, good luck to the scientists in their endeavor to treat these horrible diseases.
